SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies shares surged following record quarterly results that significantly outperformed earnings and revenue estimates, alongside a substantial increase to its full-year revenue outlook fueled by explosive demand for AI-optimized servers. While some traders debate the long-term sustainability of the company's accounts payable-reliant growth model and margins, the dominant community sentiment remains extremely bullish regarding the company's AI-driven backlog and future performance.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The DIA is trending lower alongside broader markets as geopolitical tensions in the Middle East and rising oil prices fuel investor anxiety over inflation and potential interest rate hikes. Traders are closely monitoring Treasury yields and upcoming economic data for clarity on the Federal Reserve's policy direction.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

Edison International shares are experiencing high volatility as traders react to reports that lawmakers failed to pass a wildfire liability reform bill, leaving the utility exposed to potential legal risks. While some investors view the resulting price drop as an overreaction and a buying opportunity, others remain cautious due to ongoing litigation and regulatory uncertainty surrounding recent wildfires.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are volatile after the company reported quarterly results that exceeded expectations and raised full-year guidance, with investors struggling to reconcile the positive earnings beat against the stock's recent sharp run-up and cautious outlook on AI revenue acceleration. The erratic price action led to significant debate among traders regarding whether the drop represents a buying opportunity or a correction of an overextended valuation.

PG&E Corp. operates as a holding company, which engages in generation, transmission, and distribution of electricity and natural gas to customers. It specializes in energy, utility, power, gas, electricity, solar, and sustainability. The company was founded on November 17, 1995 and is headquartered in Oakland, CA.

PG&E Corp.

PG&E shares experienced significant volatility following reports that California lawmakers blocked a legislative effort to provide wildfire liability protection for utilities. While some traders view the resulting selloff as an overreaction and speculate on a potential recovery or short squeeze, others have downgraded the stock due to lingering financial and wildfire liability risks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The QQQ is trending lower as investors react to rising oil prices and surging U.S. Treasury yields, fueled by concerns over escalating military tensions in the Middle East and uncertainty regarding Federal Reserve rate policy. Community sentiment remains cautious as traders debate whether the market will face a correction or see a recovery driven by AI-related earnings strength.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is trending lower as market participants react to escalating geopolitical tensions in the Middle East, rising crude oil prices, and climbing U.S. Treasury yields. Traders are expressing widespread concern over potential Federal Reserve interest rate hikes and the broader economic impact of these mounting macro headwinds.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

The conversation is centered on anticipation for the Phase 3 ORIGIN 3 final eGFR analysis, with traders debating whether upcoming data will prove drug durability and kidney-function benefits. While some express concern over recent insider selling, bullish sentiment remains strong among many who view the upcoming readout as a potential catalyst for a significant valuation rerating or acquisition.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The primary catalyst for VOO trending is heightened market anxiety over geopolitical instability in the Middle East and concerns regarding bond market volatility, which has led traders to debate whether current market valuations are sustainable. Discussion is fragmented between investors advocating for a "VOO and chill" long-term compounding approach and those speculating on an imminent correction due to concerns about the U.S. economy, debt levels, and the perceived overvaluation of AI-driven tech stocks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing intense investor scrutiny ahead of its earnings report, with sentiment divided between those anticipating a major AI-driven breakout and traders concerned about the stock's recent underperformance relative to other semiconductor peers. Conversations remain highly volatile, with frequent debates focusing on the sustainability of AI demand and the impact of the company's management and guidance on share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million.
Lakewood-Amedex (NASDAQ:LABT)read more...

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million.
Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4% to $32.8.read more...

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million.
Lakewood-Amedex (NASDAQ:LABT) shares movedread more...

Antibiotic Resistance Crisis Drives Spotlight to Lakewood-Amedex Biotherapeutics and Its Phase 2-Ready Antimicrobial Candidate

As antimicrobial resistance (AMR) continues to rank among the world's most urgent public health challenges, Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is highlighting new laboratory data supporting the potential of its lead drug candidate, Nu-3, following renewed national attention on combating drug-resistant infections. The company's announcement comes after the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) discussed priorities for the next five-year National Action Plan designed to strengthen the U.S. response to antimicrobial resistance.

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential...

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel PR Newswire...

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance PR Newswire SARASOTA, Fla., July 7, 2026 Company...

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a...

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for...

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum PR Newswire SARASOTA, Fla., June 16, 2026 SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

LABT Lakewood-Amedex Biotherapeutics Inc.

Fundamentals

Latest LABT News